Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial

Real-Life Experience of Molnupiravir in Hospitalized Patients Who Developed SARS-CoV2-Infection: Preliminary Results from CORACLE Registry

“…Moreover, in our study we did not find any differences in terms of mortality or risk of progression to respiratory failure between vaccinated or unvaccinated patients treated with molnupiravir. Recently Khoo et al, published data regarding the effect of molnupiravir on virological response by SARS-CoV-2 variant and in vaccinated patients [ 19 ]. In this study viral load reductions during molnupiravir treatment were observed in both vaccinated and unvaccinated individuals [ 19 ].…”

“…Recently Khoo et al, published data regarding the effect of molnupiravir on virological response by SARS-CoV-2 variant and in vaccinated patients [ 19 ]. In this study viral load reductions during molnupiravir treatment were observed in both vaccinated and unvaccinated individuals [ 19 ]. In addition, Khoo and colleagues stated that no participants in the molnupiravir group were hospitalized [ 19 ].…”

“…In this study viral load reductions during molnupiravir treatment were observed in both vaccinated and unvaccinated individuals [ 19 ]. In addition, Khoo and colleagues stated that no participants in the molnupiravir group were hospitalized [ 19 ]. Interestingly Wong and colleagues in their real-life use of molnupiravir showed in the subgroup analyses of study outcomes stratified by age and vaccination status, results comparing molnupiravir use and non-use were significant for reduced risks of all-cause mortality and in-hospital disease progression among patients older than 60 years [ 17 ].…”

Learning and confirming in publicly funded antiviral trials

“…Reporting the phase 2 results from the UK AGILE CST-2 study of molnupiravir for SARS-CoV-2 in The Lancet Infectious Diseases , Saye H Khoo and colleagues 1 present output from a platform trial with public funding that has taken an approach inspired by commercial drug developers. The COVID-19 pandemic exposed our lack of potent oral antivirals and, given the previous two decades of outbreaks of RNA viruses, including SARS-CoV, MERS-CoV, and Ebola virus, one could argue that we should have been better prepared.…”

“…In the study by Khoo and colleagues, 1 molnupiravir shortened the time to negative PCR compared with placebo (8 days [95% CI 8–9] vs 11 days [10–11]), although the predefined threshold for recommending molnupiravir for further testing was not reached. As half the participants in the study were unvaccinated and the median age of the study cohort was 43 years (IQR 28–55), whether results will be similar in a largely vaccinated, older population remains to be seen.…”